Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.2BCash on Hand
CF+ Cash Runway
Follow ROIV by emailGet an email when ROIV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ROIV, unsubscribe in one click. Privacy
📣 What ROIV Says Is Next
second half of · “Topline Phase 3 data in NIU and Phase 3 study initiation in CS are expected in the second half of calendar year 2026.”
Company press release, Apr 2, 2026 · SEC filing
2H 2026 · “Upcoming Brepocitinib Catalysts Over the Next 18 Months Pivotal / Potentially Registrational Proof of Concept / Other Early 2026 Expected NDA filing in DM 2026 2H 2026 Topline data in NIU 1H 2027 Potential sNDA filing in NIU 1H 2026 Topline data in CS 63 2027 Early 2027 Potential commercial launch in DM Note: All drugs are investigational and subject to regulatory approvals.”
Company press release, Dec 11, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q2 results with $4.2 billion in cash and equivalents as of September 30. LISRAYA generated $31.0 million net product revenue in its first 5 weeks after August launch. IMVT-1402 600 mg met its Period 2 RA primary endpoint (92.5% vs. 75.6% placebo), but Sjögren's advancement is unlikely beyond the Phase 2. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 21, 2026 ·
Clinical trial Positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis: both met the primary endpoint, with hazard ratios of 0.27 and 0.22 for treatment failure vs. placebo (p<0.0001). Priovant plans an sNDA filing in 1H 2027. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Shareholder vote Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors, ratified Ernst & Young LLP as independent auditor for fiscal year ending March 31, 2027, and approved executive compensation on an advisory basis at the September 16, 2026 annual meeting. Form 8-K · SEC filing
Sep 8, 2026 ·
Clinical trial Announced positive Phase 2 PHocus results for mosliciguat in PH-ILD, with a -56.3% placebo-adjusted PVR reduction (p<0.0001) at Week 16. Also met secondary endpoints and started the Phase 3 PHrontier study. Form 8-K · SEC filing · Press release
Aug 28, 2026 ·
Regulatory FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, with commercial launch available today. Wholesale acquisition cost is $35,000 for a 30-count bottle of 30 mg tablets. Form 8-K · SEC filing · Press release
Aug 27, 2026 ·
Regulatory FDA approved LISRAYA (brepocitinib) 30 mg once-daily for adults with dermatomyositis, submitted by subsidiary Priovant; the drug is now available in the U.S. In the Phase 3 VALOR trial, 55% of patients on LISRAYA reached moderate or better Total Improvement Score with minimal or no steroid use, versus 30% on placebo. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2020 · Phase 2 · Results Expected · A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ROIV holds $4.2B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure:0 · Low
No operating cash burn in latest filings
Recent financing filings on SEC EDGAR:
Oct 3, 2025 · Shelf registration with ATM program, up to $400M · S-3ASR
Share count 724,561,460 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ROIV and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.